TY - T1的三联疗法试验在慢性阻塞性肺病:公关ecision medicine opportunity JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01848-2018 VL - 52 IS - 6 SP - 1801848 AU - Suissa, Samy AU - Ariel, Amnon Y1 - 2018/12/01 UR - //www.qdcxjkg.com/content/52/6/1801848.abstract N2 - The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy document for the treatment of chronic obstructive pulmonary disease (COPD) suggests that, after bronchodilator treatment with both long-acting muscarinic antagonists and long-acting inhaled β-agonists (LAMA/LABA), the addition of inhaled corticosteroids (ICS) should be reserved for patients with frequent moderate or severe COPD exacerbations [1]. The GOLD group emphasises the scarcity of evidence and the need for systematic research on this escalation from dual bronchodilator to triple therapy (LAMA/LABA/ICS) [2].Recent trials comparing triple therapy with LAMA/LABA in COPD reveal a peculiar pattern in the timing of exacerbations, with the benefit of triple therapy exclusively in the first month, suggesting a precision medicine opportunity in COPD treatment http://ow.ly/WBFb30m9ZeM ER -